Navigation Links
Cholesterol Drug Zetia Doesn't Cut Heart Attack Risk: Study
Date:1/14/2008

Results might also pertain to Vytorin, which contains Zetia, experts say

MONDAY, Jan. 14 (HealthDay News)-- The long-awaited results of a trial of Zetia, a cholesterol-lowering drug prescribed to about a million Americans, shows the drug confers no medical benefit to users.

In fact, the pace at which artery-clogging plaques formed within vessels almost doubled in patients taking Zetia (ezetimibe) along with another cholesterol-lowering drug, Zocor (simvastatin), compared to those taking Zocor alone, the study found.

The two medications -- ezetimibe plus simvastatin -- are also marketed in one prescription pill, called Vytorin. About 60 percent of U.S. patients who are taking Zetia now receive the drug as part of Vytorin.

But the new two-year trial of 720 patients sheds doubt on whether it makes any sense for people battling cholesterol to take Vytorin versus Zocor alone, experts said. The study was funded by the two companies that make Zetia, Merck and Schering-Plough.

"This wraps it up," said Dr. Steven E. Nissen, chairman of cardiology at the Cleveland Clinic. "That's all there is. There just isn't any evidence that adding ezetimibe to simvastatin produces any advantage."

No one is disputing that Zetia can lower levels of LDL "bad" cholesterol by 15 percent to 20 percent -- that had been shown in previous trials. However, whether that reduction led to any greater lowering of heart attack or stroke risk had remained unclear.

The new ENHANCE trial -- which involved patients with a genetic condition that causes abnormally high levels of blood cholesterol -- found no such added benefit. According to a statement released by the two drug companies Monday, researchers found no statistically significant difference in heart attacks or stroke among trial participants who took Zetia plus Zocor, a widely used cholesterol-lower drug, versus those who got Zocor alone.

The study also n
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

4

GOOD

Page: 1 2 3

Related medicine news :

1. Seven New Cholesterol Genes Discovered
2. Corazonas Launches First and Only Cholesterol-Reducing Potato Chips
3. High triglycerides, other cholesterol raise risk of stroke
4. New Type of Cholesterol-Lowering Drug Shows Promise
5. Study Finds Cholesterol Fine-Tunes Hearing
6. Consumers Union Opposes Over-the-Counter Cholesterol Drug
7. Cholesterol-Stroke Relationship Puzzles Researchers
8. Knowing Heart Risk Keeps Patients on Cholesterol Drugs
9. Low Levels of Good Cholesterol May Slow Stroke Recovery
10. CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
11. Many Patients Stop Taking Cholesterol-Lowering Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cholesterol Drug Zetia Doesn't Cut Heart Attack Risk: Study
Cholesterol Drug Zetia Doesn't Cut Heart Attack Risk: Study
(Date:2/9/2010)... television drama may be more effective in persuading young ... on the same issue, according to a new study. ... televised drama about a teen pregnancy felt more vulnerable ... to more support for using birth control. , However, ... caused by teen pregnancies were unmoved, and had no ...
(Date:2/9/2010)... from a large-scale study of key antimalarial medicines ... high percentage of medicines circulating on national markets ... to the growth of drug-resistant strains of ... malaria. The findings, released today by the Promoting ... program implemented by the US Pharmacopeial Convention (USP), ...
(Date:2/9/2010)... , Feb. 9 The following ... Blackwell : ,, "Reversing the childhood obesity epidemic will ... Michelle Obama demonstrated today. ,, "As the ... schools loaded with chips and soda -- and few ... however, that bleak food landscape extends far beyond the ...
(Date:2/9/2010)... WEST PALM BEACH, Fla. , Feb. 9 /PRNewswire-USNewswire/ ... a grant awarded to the School District of Palm ... eat right and get fit. The Robert Wood Johnson Foundation ... opportunities for physical activity and access to affordable healthy foods ... and Palm Springs communities. Based on a rigorous ...
(Date:2/9/2010)... iPhone application created by UH researchers is providing ... world. Those annual rankings of America,s fattest and ... host of indirect indicators may soon have a ... the University of Houston provides objective data. , ... from Apple,s "App Store," allows users to keep ...
Breaking Medicine News(10 mins):Health News:TV drama can be more persuasive than news program, study finds 2Health News:TV drama can be more persuasive than news program, study finds 3Health News:TV drama can be more persuasive than news program, study finds 4Health News:One-third of antimalarial medicines sampled in 3 African nations found to be substandard 2Health News:One-third of antimalarial medicines sampled in 3 African nations found to be substandard 3Health News:Planting Seeds to Fight Childhood Obesity 2Health News:Phone app providing real-time statistics on physical activity around the world 2Health News:Phone app providing real-time statistics on physical activity around the world 3
... for Occupation Health and Safety Development says that women who ... cancer. Citing a study by US-based Fred Hutchinson Cancer Research ... up work in the graveyard shift - usually from 6 ... usually done at call centers placed them at a high ...
... now found to play a role in reversing the aging ... new age spots in women. ,A team of ... stable n-acetyl glucosamine have shown to reduce the melanin content ... damage treatment. ,For many women, accumulated sun exposure ...
... have uncovered that missing portions of 2 chromosomes located at ... ,The senior author Walter J. Curran Jr., M.D., ... of Thomas Jefferson University in Philadelphia, have found a paradigm ... known as gliomas. ,Reporting last week in the ...
... Glaxo Kline has found to be effective in preventing cervical ... (HPVs). ,Researchers suggested that HPV vaccination were ... the subjects. ,In the past 20 years, advances ... discovery of the link between HPV and cervical cancer. Two ...
... dietary restrictions, ensuring that no gluten, a product found in ... this may soon come to an end. Researchers in the ... food processing -- AN-PEP -- may be able to break ... intestine. This information could be vital because the small intestine ...
... of Radiotherapy and Oncology of the All-India Institute of ... stating that her ad hoc appointment was terminated due ... Institute recently. ,In a letter to Anbumani ... Dr. Ajita Gill said that although the "vicious ...
Other Medicine News:Health News:Study Finds - UV Damaged Skin could be Possibly Treated with Glucosamine 2Health News:Study Finds - UV Damaged Skin could be Possibly Treated with Glucosamine 3Health News:Missing Chromosomes Revealed Brain Tumor Therapy Effect – Research Find 2Health News:Missing Chromosomes Revealed Brain Tumor Therapy Effect – Research Find 3Health News:Celiac Disease Sufferers See an End to their Misery 2
(Date:2/8/2010)... Feb. 8 BD Diagnostics, a ... the launch of BD Microtainer® MAP Microtube for Automated ... to improve the safety, accuracy and turnaround time of ... that can be difficult to access, such as infants, ... Microtainer MAP product is also the first microtube to ...
(Date:2/8/2010)... Hanger Orthopedic Group, Inc. (NYSE: HGR ... of operations for the year ended December 31, 2009 ... Company plans to issue a press release announcing the results ... Wednesday, February 10, 2010 , after the close of ... 9:00 a.m., EST , on Thursday, February 11, ...
(Date:2/8/2010)... Feb. 8 Connectyx Technologies Holdings ... advertising contract with SkyMall Inc. SkyMall produces the ... major airlines seat pockets. SkyMall has an annual ... featuring the MedFlash ® Personal Health Manager ... of contents in the front section of the ...
Breaking Medicine Technology:BD Launches New Device Designed to Improve Safety, Accuracy and Turnaround Time of Blood Collection in Patients with Fragile Veins 2Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call 2Connectyx Announces MedFlash(R) Advertising Contract with SkyMall Inc. 2Connectyx Announces MedFlash(R) Advertising Contract with SkyMall Inc. 3livethesource 28TM 29 the Worlds First and Only Patented Fully Nano Encapsulated Liquid Vitamin Mineral and Herbal Supplement Now Available in Dal 51780 1livethesource 28TM 29 the Worlds First and Only Patented Fully Nano Encapsulated Liquid Vitamin Mineral and Herbal Supplement Now Available in Dal 51780 2livethesource 28TM 29 the Worlds First and Only Patented Fully Nano Encapsulated Liquid Vitamin Mineral and Herbal Supplement Now Available in Dal 51780 3CNCB Post Graduate Studies in Clinical Nutrition 28PGSCN 29 Program is Now Available Online 51778 1CNCB Post Graduate Studies in Clinical Nutrition 28PGSCN 29 Program is Now Available Online 51778 2Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi Year Marketing Agreement with Phase Forward 13043 1Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi Year Marketing Agreement with Phase Forward 13043 2Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi Year Marketing Agreement with Phase Forward 13043 3
... Studies with Monoclonal Antibody,Targeting Interleukin-9 (IL-9); Preclinical ... Developing Potential Asthma,Therapies, GAITHERSBURG, Md., May 24, ... presentation of data,highlighting recent progress within the ... Phase 1 clinical,studies with its monoclonal antibody ...
... HILL, N.C., May 25, 2007 /PRNewswire/ -- ... pharmaceutical product at play,pharmaceutical firms need to ... early. Companies that master,their communication planning and ... marketplace. , According to research and consulting ...
Other Medicine Technology:MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 2MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 3MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 6MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 7Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 2Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 3
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses....
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Medicine Products: